Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.40 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | ABL1 | P00519 | 4/20 | 0.39 |
| ▸ | ABL2 | P42684 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19553770 | 0.82 | ADORA2A (0.49) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1375991 | 0.80 | ADORA2A (0.51) | JAK2JAK1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2951838 | 0.80 | ADORA2A (0.51) | JAK2JAK1ALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL6821629 | 0.78 | ADORA2A (0.50) | JAK2JAK1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL10600446 | 0.78 | ADORA2A (0.53) | JAK2JAK1ALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL7659256 | 0.72 | ABL1 (0.39) | SRCEGFRABL1ABL2JAK2 | |
| Hydrochloric Acid SCHEMBL7659251 | 0.72 | ABL1 (0.39) | SRCEGFRABL1ABL2JAK2 | |
| Hydrochloric Acid SCHEMBL7659259 | 0.72 | ABL1 (0.39) | SRCEGFRABL1ABL2JAK2 | |
| Hydrochloric Acid SCHEMBL7843046 | 0.72 | ABL1 (0.39) | SRCEGFRABL1ABL2JAK2 | |
| SCHEMBL15720194 | 0.72 | ADORA2A (0.70) | SRCEGFRABL1ABL2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1113020-B1 | Nucleosides and oligonucleotides containing boron clusters | UNIV EMORY (US) | 2009-10-28 | — | — | EP | disclosed |
| US-6583122-B2 | Use in boron neutron capture therapy (BNCT) and diagnostic purposes; treating cancer, viral infections such as HIV, hepatitis B virus | EMORY UNIVERSITY | 2003-06-24 | — | — | US | disclosed |
| US-20020160969-A1 | Nucleosides and oligonucleotides containing boron clusters | DEPARTMENT OF VETERANS AFFAIRS | 2002-10-31 | — | — | US | disclosed |
| EP-0731808-B1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | UNIV EMORY (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-1113020-A2 | Nucleosides and oligonucleotides containing boron clusters | EMORY UNIVERSITY (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6180766-B1 | OLIGONUCLEOTIDE WITH UNCHARGED INTERNUCLEOTIDE LINKAGE(S) OF 3',5'-O,O-((CARBORAN-1-YL-METHYL)PHOSPHONATE); MADE BY REACTING O-METHYL(O-CARBORAN-1-YL)METHYL PHOSPHONATE WITH PROTECTED NUCLEOSIDE; USE IN BORON NEUTRON CAPTURE THERAPY | DEPARTMENT OF VETERANS AFFAIRS | 2001-01-30 | — | — | US | disclosed |
| US-5872107-A | ANTICARCINOGENIC AGENTS CAPTURE THERAPY FOR TUMORS | EMORY UNIVERSITY (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0788364-A4 | TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY | UNIV EMORY (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0788364-A1 | TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY | EMORY UNIVERSITY (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0731808-A4 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | UNIV EMORY (US) | 1997-04-02 | — | — | EP | disclosed |
| US-5599796-A | USING BORON CLUSTER-CONTAINING NUCLEOSIDES OR OLIGONUCLEOTIDES; PARTICULARLY EFFECTIVE FOR BLADDER, PROSTATE AND KIDNEY | EMORY UNIVERSITY (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0731808-A1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | EMORY UNIVERSITY (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996014073-A1 | TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY | EMORY UNIVERSITY (US) | 1996-05-17 | — | — | WO | disclosed |
| WO-1995015333-A1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | EMORY UNIVERSITY (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160969-A1 | Nucleosides and oligonucleotides containing boron clusters | NUDT1, NTPCR, NAMPT | SRC 4441/4885EGFR 2262/4885ABL1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.